Ki Jung Ahn

Ki Jung Ahn

Auto-generated profile, based on publicly available information

Ki Jung Ahn

Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YKYongkan Ki
Yongkan Ki
WKWontaek Kim
Wontaek Kim
HCHeunglae Cho
Heunglae Cho
KAKijung Ahn
Kijung Ahn
YCYoungmin Choi
Youngmin Choi
DKDongwon Kim
Dongwon Kim
Ki Y, et al. J Korean Med Sci. 2014 Oct;29(10):1372-1378. http://dx.doi.org/10.3346/jkms.2014.29.10.1372

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YCYunseon Choi
Yunseon Choi
SPSung Kwang Park
Sung Kwang Park
KAKi Jung Ahn
Ki Jung Ahn
HCHeunglae Cho
Heunglae Cho
TKTae Hyun Kim
Tae Hyun Kim
Yun-Han LeeYun-Han Lee
Yun-Han Lee
Choi Y, et al. J Korean Med Sci. 2016 Jun;31(6):886-891. http://dx.doi.org/10.3346/jkms.2016.31.6.886

1 February 2019 in Clinical Breast Cancer
Verified
Journal Article
Closed access
WCWon Kyung Cho
Won Kyung Cho
WPWon Park
Won Park
DCDoo Ho Choi
Doo Ho Choi
YKYong Bae Kim
Yong Bae Kim
JKJin Hee Kim
Jin Hee Kim
KAKi Jung Ahn
Ki Jung Ahn

1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
ALAnbok Lee
Anbok Lee
HKHee Yeon Kim
Hee Yeon Kim
TKTae Hyun Kim
Tae Hyun Kim
KAKi Jung Ahn
Ki Jung Ahn
HCHeunglae Cho
Heunglae Cho
YCYunseon Choi
Yunseon Choi
Lee A, et al. J Korean Med Sci. 2022 Feb;37(8):e64. https://doi.org/10.3346/jkms.2022.37.e64

17 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DKDa Som Kim
Da Som Kim
DKDong Wook Kim
Dong Wook Kim
YHYoung Jin Heo
Young Jin Heo
JBJin Wook Baek
Jin Wook Baek
YLYoo Jin Lee
Yoo Jin Lee
TKTaewoo Kang
Taewoo Kang
This study investigated the role of BRAF mutation analysis in thyroid fine-needle aspiration (FNA) samples compared to ultrasonographic and cytological diagnoses. A total 316 patients underwent ultrasonography (US)-guided FNA with BRAFV600E mutation analysis to diagnose thyroid nodules. One hundred sixteen patients with insufficient US images (n = 6), follow-up loss (n = 43), or unknown final diagnosis (n = 67) were excluded from the study. Comparisons between US diagnoses, cytological diagnoses, and BRAF mutation analysis were performed. Of 200 thyroid nodules, there was US diagnosis with 1 false negative and 11 false positive cases, cytological diagnosis with 10 false negative and 2 false positive cases, and BRAFV600E mutation analysis with 19 false negative and 2 false positive cases. The sensitivity, specificity, positive and negative predictive values, and accuracy of BRAFV600E mutation analysis were 83.2%, 98.1%, 97.5%, 86.6%, and 91%, respectively. Of the 18 nodules with Bethesda category III, 9 were true positive, 6 were true negative, 3 was a false negative, and none were false positive on BRAF mutation analysis. In conclusion, we recommend that BRAFV600E mutation analysis only be performed for evaluating thyroid nodules with Bethesda category III, regardless of US diagnosis.

1 January 2025 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
HLHyung-Sik Lee
Hyung-Sik Lee
SKSungmin Kim
Sungmin Kim
HKHyunjung Kim
Hyunjung Kim
KAKi-Jung Ahn
Ki-Jung Ahn
HPHye Won Park
Hye Won Park
YCYunseon Choi
Yunseon Choi
Lee HS, et al. Ann Surg Treat Res. 2025 Nov;109(5):286-292. https://doi.org/10.4174/astr.2025.109.5.286